JPMorgan Chase & Co. Buys 126,752 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

JPMorgan Chase & Co. raised its position in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 1,968.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 133,191 shares of the biopharmaceutical company’s stock after acquiring an additional 126,752 shares during the period. JPMorgan Chase & Co. owned approximately 0.24% of Marinus Pharmaceuticals worth $234,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. abrdn plc grew its holdings in Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after buying an additional 1,578,329 shares in the last quarter. Suvretta Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after acquiring an additional 1,253,901 shares during the period. Franklin Resources Inc. grew its stake in shares of Marinus Pharmaceuticals by 34.9% in the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after acquiring an additional 1,219,871 shares in the last quarter. GSA Capital Partners LLP increased its position in Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter worth about $727,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Analysts Set New Price Targets

MRNS has been the topic of a number of recent research reports. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. HC Wainwright restated a “neutral” rating and issued a $2.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. StockNews.com assumed coverage on shares of Marinus Pharmaceuticals in a research report on Wednesday. They set a “sell” rating for the company. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Marinus Pharmaceuticals has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Up 0.4 %

NASDAQ MRNS opened at $0.54 on Friday. The firm has a market capitalization of $29.96 million, a PE ratio of -0.22 and a beta of 1.03. The stock’s 50 day moving average is $0.41 and its 200 day moving average is $0.95. Marinus Pharmaceuticals, Inc. has a twelve month low of $0.22 and a twelve month high of $10.50.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.